Meropenem Steriscience (Meropenem)

Meropenem inhibits bacterial cell‑wall synthesis by binding to penicillin‑binding proteins. This blocks the cross‑linking of peptidoglycan strands, weakening the wall and causing osmotic lysis of the bacterium. Its structure resists most β‑lactamases, giving it activity against many resistant Gram‑negative and Gram‑positive organisms.

The specific dose and infusion rate of Meropenem Steriscience are determined by the prescribing clinician based on infection severity, pathogen susceptibility, patient weight, renal function, and other clinical factors. Healthcare professionals tailor the regimen to achieve optimal therapeutic outcomes.

Safety data for Meropenem in pregnancy and lactation are limited, and the product carries an unknown pregnancy category. It should only be used if the potential benefit justifies any potential risk to the fetus or infant, and clinicians should assess each case individually.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where required) and necessary import documentation.

Meropenem shares the carbapenem class’s broad‑spectrum activity and β‑lactamase stability, but it offers a slightly lower risk of neurotoxicity compared with imipenem and a convenient dosing schedule. Compared with ertapenem, Meropenem provides better coverage against Pseudomonas aeruginosa, making it suitable for more severe hospital‑acquired infections.

Meropenem Steriscience must be stored refrigerated at 2‑8 °C. Keep the vials in their original packaging, protect them from light, and avoid freezing or shaking. Once reconstituted, use the solution within the time frame specified in the product labeling and maintain cold‑chain conditions during transport.

The medication is supplied as an injectable solution for intravenous infusion. It is typically administered over a 15‑30‑minute infusion period, but the exact rate and duration are determined by the treating physician based on the infection type, patient condition, and renal function.

Serious adverse events include seizures, especially in patients with pre‑existing CNS disorders, severe allergic reactions such as anaphylaxis, Clostridioides difficile‑associated colitis, and significant renal or hepatic impairment. Prompt recognition and discontinuation are essential if any of these events occur.

Patients with a known hypersensitivity to Meropenem, other carbapenems, or any β‑lactam antibiotics should avoid this product. Caution is also advised for individuals with a history of seizures, severe renal or hepatic dysfunction, or those receiving interacting medications listed under major interactions.